A federal outside panel voted Thursday to relax rules on seven peptides, including BPC-157 and TB-500. The vote was close. It is non-mandatory. The FDA has given no signal on whether it will follow the advice. The move came after weeks of public comment sessions. Wellness backers pressed strongly for wider access. RFK Jr. was among them. Critics say these compounds have weak safety evidence or help for most uses. The call could redefine how the agency handles a part of the wellness market that is expanding rapidly. Watchers are waiting to see if the regulator moves in step. A representative for the regulator offered no firm timeline for a next step. Supporters argue the change would expand access to products users find useful. Opponents warn that looser rules could leave gaps in oversight across a fast-scaling market. The vote only opens the door to a change, and the last word rests with the FDA.